Frank  Clyburn net worth and biography

Frank Clyburn Biography and Net Worth

Frank Clyburn is executive vice president and president of Human Health for Merck. He is responsible for all Human Health marketing and commercial operations globally and the P&L for the company’s portfolio of medicines and vaccines.

Prior to this role, Frank was chief commercial officer for Merck, responsible for Human Health commercial operations and the Human Health P&L. From 2013 to 2018, Frank was the inaugural president of the company’s global oncology business. He led the creation of this fully integrated global business unit, the worldwide launch of Merck’s immuno-oncology medicine and the establishment of Merck as a leader in oncology.

Previously, he was the president of the primary care and women’s health businesses and market access function. He also led the company’s global pharmaceutical franchises and lived in Shanghai and Lucerne. Frank joined the company in 2008 to lead its biologics business. 

Before joining Merck, Frank was vice president of the oncology and internal medicine business units at Sanofi Aventis and held a wide range of leadership roles with that company, in addition to leading the integration of Sanofi and Aventis. 

Frank received his Master of Business Administration degree from Arizona State University and his Bachelor of Arts degree from Franklin & Marshall College. He currently serves on the board of directors for the European Federation of Pharmaceutical Industries and Associations (EFPIA) and DuPont. Frank also served as chairman to the Thomas Edison State University board of trustees.

What is Frank Clyburn's net worth?

The estimated net worth of Frank Clyburn is at least $10.36 million as of August 5th, 2020. Mr. Clyburn owns 99,639 shares of Merck & Co., Inc. stock worth more than $10,358,470 as of September 28th. This net worth evaluation does not reflect any other assets that Mr. Clyburn may own. Learn More about Frank Clyburn's net worth.

How do I contact Frank Clyburn?

The corporate mailing address for Mr. Clyburn and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Frank Clyburn's contact information.

Has Frank Clyburn been buying or selling shares of Merck & Co., Inc.?

Frank Clyburn has not been actively trading shares of Merck & Co., Inc. during the last ninety days. Most recently, Frank Clyburn sold 39,762 shares of the business's stock in a transaction on Monday, November 1st. The shares were sold at an average price of $87.87, for a transaction totalling $3,493,886.94. Learn More on Frank Clyburn's trading history.

Who are Merck & Co., Inc.'s active insiders?

Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.

Are insiders buying or selling shares of Merck & Co., Inc.?

During the last year, Merck & Co., Inc. insiders bought shares 3 times. They purchased a total of 150 shares worth more than $15,886.16. During the last year, insiders at the sold shares 24 times. They sold a total of 1,679,103 shares worth more than $177,166,367.00. The most recent insider tranaction occured on August, 14th when EVP Steven Mizell sold 4,250 shares worth more than $463,292.50. Insiders at Merck & Co., Inc. own 0.2% of the company. Learn More about insider trades at Merck & Co., Inc..

Information on this page was last updated on 8/14/2023.

Frank Clyburn Insider Trading History at Merck & Co., Inc.

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2021Sell39,762$87.87$3,493,886.94View SEC Filing Icon  
8/5/2020Sell18,876$81.55$1,539,337.8099,639View SEC Filing Icon  
5/7/2019Sell25,000$77.73$1,943,250.0092,604View SEC Filing Icon  
See Full Table

Frank Clyburn Buying and Selling Activity at Merck & Co., Inc.

This chart shows Frank Clyburn's buying and selling at Merck & Co., Inc. by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Merck & Co., Inc. Company Overview

Merck & Co., Inc. logo
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Read More

Today's Range

Now: $104.29
Low: $103.78
High: $104.97

50 Day Range

MA: $107.74
Low: $103.96
High: $111.34

2 Week Range

Now: $104.29
Low: $86.02
High: $119.65


4,758,794 shs

Average Volume

7,551,088 shs

Market Capitalization

$264.64 billion

P/E Ratio


Dividend Yield



Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
U.S. Pentagon consultant explains full story here…